Role of microRNAs in diabetes and its cardiovascular complications

Cardiovascular Research

Volumn 93, Issue 4, 2012, Pages 583-593

  Shantikumar, Saran ^a   Caporali, Andrea ^a   Emanueli, Costanza ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Cardiovascular complications; Diabetes; MicroRNAs

Indexed keywords

MICRORNA;

CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DIABETIC RETINOPATHY; DIABETOGENESIS; ENDOTHELIAL DYSFUNCTION; GENE EXPRESSION; GLUCOSE METABOLISM; HUMAN; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RNA ANALYSIS;

ANIMALS; BIOLOGICAL MARKERS; DIABETES COMPLICATIONS; DIABETIC ANGIOPATHIES; DIABETIC CARDIOMYOPATHIES; DIABETIC RETINOPATHY; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; HUMANS; INSULIN RESISTANCE; MICRORNAS;

EID: 84857932052     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvr300     Document Type: Review

References (121)

1. Adams KF, Schatzkin A, Harris TB, Kipnis V, Mouw T, Ballard-Barbash R et al. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med 2006;355:763-778. (Pubitemid 44285582)
2. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 9999;87:4-14.
3. Centers for Disease Control and Prevention. National Diabetes Factsheet: National Estimates and General Information on Diabetes and Prediabetes in the United States. Atlanta, GA: Department of Health and Human Services, Centers for Disease Control and Prevention; 2011.
4. Ilonen J, Akerblom HK. New technologies and genetics of type 1 diabetes. Diabetes Technol Ther 1999;1:205-207.
5. Kahn SE. Clinical review 135: the importance of beta-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab 2001;86:4047-4058. (Pubitemid 32848511)
6. Winer N, Sowers JR. Epidemiology of diabetes. J Clin Pharmacol 2004;44:397-405. (Pubitemid 38396785)
7. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993;75:843-854. (Pubitemid 24014542)
8. Wightman B, Ha I, Ruvkun G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell 1993; 75:855-862. (Pubitemid 24014543)
9. Zeng Y, Cullen BR. Recognition and cleavage of primary microRNA transcripts. Methods Mol Biol 2006;342:49-56.
10. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 2004;5:522-531. (Pubitemid 38868508)
11. van Rooij E. The art of microRNA research. Circ Res 2011;108:219-234.
12. YangW, Lee DY, Ben-David Y. The roles of microRNAs in tumorigenesis and angiogenesis. Int J Physiol Pathophysiol Pharmacol 2011;3:140-155.
13. Nicolas FE, Lopez-Martinez AF. MicroRNAs in human diseases. Recent Pat DNA Gene Seq 2010;4:142-154.
14. Lorenzen JM, Haller H, Thum T. MicroRNAs as mediators and therapeutic targets in chronic kidney disease. Nat Rev Nephrol 2011;7:286-294.
15. Poy MN, Eliasson L, Krutzfeldt J, Kuwajima S, Ma X, Macdonald PE et al. A pancreatic islet-specific microRNA regulates insulin secretion. Nature 2004;432:226-230. (Pubitemid 39545853)
16. Li Y, Xu X, Liang Y, Liu S, Xiao H, Li F et al. miR-375 enhances palmitate-induced lipoapoptosis in insulin-secreting NIT-1 cells by repressing myotrophin (V1) protein expression. Int J Clin Exp Pathol 2010;3:254-264.
17. Norlin S, Ahlgren U, Edlund H. Nuclear factor-{kappa}B activity in {beta}-cells is required for glucose-stimulated insulin secretion. Diabetes 2005;54:125-132. (Pubitemid 40105103)
18. Gupta S, Sen S. Myotrophin-kappaB DNA interaction in the initiation process of cardiac hypertrophy. Biochim Biophys Acta 2002;1589:247-260. (Pubitemid 34603296)
19. El Ouaamari A, Baroukh N, Martens GA, Lebrun P, Pipeleers D, van Obberghen E. miR-375 targets 3′-phosphoinositide-dependent protein kinase-1 and regulates glucose-induced biological responses in pancreatic beta-cells. Diabetes 2008;57: 2708-2717.
20. Poy MN, Hausser J, Trajkovski M, Braun M, Collins S, Rorsman P et al. miR-375 maintains normal pancreatic alpha-and beta-cell mass. Proc Natl Acad Sci USA 2009;106: 5813-5818.
21. Zhao H, Guan J, Lee HM, Sui Y, He L, Siu JJ et al. Up-regulated pancreatic tissue microRNA-375 associates with human type 2 diabetes through beta-cell deficit and islet amyloid deposition. Pancreas 2010;39:843-846.
22. Plaisance V, Abderrahmani A, Perret-Menoud V, Jacquemin P, Lemaigre F, Regazzi R. MicroRNA-9 controls the expression of Granuphilin/Slp4 and the secretory response of insulin-producing cells. J Biol Chem 2006;281:26932-26942. (Pubitemid 44401722)
23. Lovis P, Gattesco S, Regazzi R. Regulation of the expression of components of the exocytotic machinery of insulin-secreting cells by microRNAs. Biol Chem 2008;389: 305-312. (Pubitemid 351329024)
24. Baroukh N, Ravier MA, Loder MK, Hill EV, Bounacer A, Scharfmann R et al. MicroRNA-124a regulates Foxa2 expression and intracellular signaling in pancreatic beta-cell lines. J Biol Chem 2007;282:19575-19588. (Pubitemid 47100119)
25. Puigserver P, Rodgers JT. Foxa2, a novel transcriptional regulator of insulin sensitivity. Nat Med 2006;12:38-39. (Pubitemid 43050058)
26. Guay C, Roggli E, Nesca V, Jacovetti C, Regazzi R. Diabetes mellitus, a microRNA-related disease? Transl Res 2011;157:253-264.
27. Lovis P, Roggli E, Laybutt DR, Gattesco S, Yang JY, Widmann C et al. Alterations in microRNA expression contribute to fatty acid-induced pancreatic beta-cell dysfunction. Diabetes 2008;57:2728-2736.
28. Roggli E, Britan A, Gattesco S, Lin-Marq N, Abderrahmani A, Meda P et al. Involvement of microRNAs in the cytotoxic effects exerted by proinflammatory cytokines on pancreatic beta-cells. Diabetes 2010;59:978-986.
29. Tang X, Muniappan L, Tang G, Ozcan S. Identification of glucose-regulated miRNAs from pancreatic {beta} cells reveals a role for miR-30d in insulin transcription. RNA 2009;15:287-293.
30. Sun LL, Jiang BG, Li WT, Zou JJ, Shi YQ, Liu ZM. MicroRNA-15a positively regulates insulin synthesis by inhibiting uncoupling protein-2 expression. Diabetes Res Clin Pract 2011;91:94-100.
31. Chan CB, De Leo D, Joseph JW, McQuaid TS, Ha XF, Xu F et al. Increased uncoupling protein-2 levels in beta-cells are associated with impaired glucose-stimulated insulin secretion: mechanism of action. Diabetes 2001;50:1302-1310. (Pubitemid 32500162)
32. Esguerra JL, Bolmeson C, Cilio CM, Eliasson L. Differential glucose-regulation of MicroRNAs in pancreatic islets of non-obese type 2 diabetes model Goto-Kakizaki rat. PLoS ONE 2011;6:e18613.
33. Goossens GH. The role of adipose tissue dysfunction in the pathogenesis of obesity-related insulin resistance. Physiol Behav 2008;94:206-218. (Pubitemid 351615418)
34. Xu P, Vernooy SY, Guo M, Hay BA. The Drosophila microRNA Mir-14 suppresses cell death and is required for normal fat metabolism. Curr Biol 2003;13:790-795. (Pubitemid 36531030)
35. Teleman AA, Maitra S, Cohen SM. Drosophila lacking microRNA miR-278 are defective in energy homeostasis. Genes Dev 2006;20:417-422. (Pubitemid 43244395)
36. Bluher M, Michael MD, Peroni OD, Ueki K, Carter N, Kahn BB et al. Adipose tissue selective insulin receptor knockout protects against obesity and obesity-related glucose intolerance. Dev Cell 2002;3:25-38. (Pubitemid 34778393)
37. He A, Zhu L, Gupta N, Chang Y, Fang F. Overexpression of micro ribonucleic acid 29, highly up-regulated in diabetic rats, leads to insulin resistance in 3T3-L1 adipocytes. Mol Endocrinol 2007;21:2785-2794. (Pubitemid 350035159)
38. Hotamisligil GS, Murray DL, Choy LN, Spiegelman BM. Tumor necrosis factor alpha inhibits signaling from the insulin receptor. Proc Natl Acad Sci USA 1994;91: 4854-4858. (Pubitemid 24177748)
39. Xie H, Lim B, Lodish HF. MicroRNAs induced during adipogenesis that accelerate fat cell development are downregulated in obesity. Diabetes 2009;58:1050-1057.
40. Esau C, Kang X, Peralta E, Hanson E, Marcusson EG, Ravichandran LV et al. MicroRNA-143 regulates adipocyte differentiation. J Biol Chem 2004;279: 52361-52365. (Pubitemid 39656612)
41. Wilfred BR,Wang WX, Nelson PT. Energizing miRNA research: a review of the role of miRNAs in lipid metabolism, with a prediction that miR-103/107 regulates human metabolic pathways. Mol Genet Metab 2007;91:209-217. (Pubitemid 46819124)
42. Ling HY, Ou HS, Feng SD, Zhang XY, Tuo QH, Chen LX et al. Changes in micro-RNA profile and effects of miR-320 in insulin-resistant 3T3-L1 adipocytes. Clin Exp Pharmacol Physiol 2009;36:e32.
43. Karbiener M, Fischer C, Nowitsch S, Opriessnig P, Papak C, Ailhaud G et al. micro-RNA miR-27b impairs human adipocyte differentiation and targets PPARgamma. Biochem Biophys Res Commun 2009;390:247-251.
44. Krishnaswami A, Ravi-Kumar S, Lewis JM. Thiazolidinediones: a 2010 perspective. Perm J 2010;14:64-72.
45. Lee EK, Lee MJ, Abdelmohsen K, Kim W, Kim MM, Srikantan S et al. miR-130 suppresses adipogenesis by inhibiting peroxisome proliferator-activated receptor gamma expression. Mol Cell Biol 2011;31:626-638.
46. Chang J, Nicolas E, Marks D, Sander C, Lerro A, Buendia MA et al. miR-122, a mammalian liver-specific microRNA, is processed from PCR mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. RNA Biol 2004;1: 106-113.
47. Esau C, Davis S, Murray SF, Yu XX, Pandey SK, Pear M et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab 2006;3:87-98.
48. Najafi-Shoushtari SH, Kristo F, Li Y, Shioda T, Cohen DE, Gerszten RE et al. MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis. Science 2010;328:1566-1569.
49. Davalos A, Goedeke L, Smibert P, Ramirez CM, Warrier NP, Andreo U et al. miR-33a/b contribute to the regulation of fatty acid metabolism and insulin signaling. Proc Natl Acad Sci USA 2011;108:9232-9237.
50. White MF. Regulating insulin signaling and beta-cell function through IRS proteins. Can J Physiol Pharmacol 2006;84:725-737. (Pubitemid 44897893)
51. Kim JA, Wei Y, Sowers JR. Role of mitochondrial dysfunction in insulin resistance. Circ Res 2008;102:401-414. (Pubitemid 351651099)
52. Ryu HS, Park SY, Ma D, Zhang J, Lee W. The induction of microRNA targeting IRS-1 is involved in the development of insulin resistance under conditions of mitochondrial dysfunction in hepatocytes. PLoS ONE 2011;6:e17343.
53. Shi B, Sepp-Lorenzino L, Prisco M, Linsley P, deAngelis T, Baserga R. Micro RNA 145 targets the insulin receptor substrate-1 and inhibits the growth of colon cancer cells. J Biol Chem 2007;282:32582-32590. (Pubitemid 350159311)
54. Huang B, Qin W, Zhao B, Shi Y, Yao C, Li J et al. MicroRNA expression profiling in diabetic GK rat model. Acta Biochim Biophys Sin (Shanghai) 2009;41:472-477.
55. Igarashi M, Wakasaki H, Takahara N, Ishii H, Jiang ZY, Yamauchi T et al. Glucose or diabetes activates p38 mitogen-activated protein kinase via different pathways. J Clin Invest 1999;103:185-195. (Pubitemid 29053136)
56. Imai G, Satoh T, Kumai T, Murao M, Tsuchida H, Shima Y et al. Hypertension accelerates diabetic nephropathy in Wistar fatty rats, a model of type 2 diabetes mellitus, via mitogen-activated protein kinase cascades and transforming growth factor-beta1. Hypertens Res 2003;26:339-347. (Pubitemid 36575789)
57. Susztak K, Raff AC, Schiffer M, Bottinger EP. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes 2006;55:225-233. (Pubitemid 43343319)
58. Avogaro A, Albiero M, Menegazzo L, de Kreutzenberg S, Fadini GP. Endothelial dysfunction in diabetes: the role of reparatory mechanisms. Diabetes Care 2011; 34(Suppl. 2):S285-S290.
59. Emanueli C, Salis MB, Pinna A, Stacca T, Milia AF, Spano A et al. Prevention of diabetes-induced microangiopathy by human tissue kallikrein gene transfer. Circulation 2002;106:993-999. (Pubitemid 34925336)
60. Waltenberger J. Impaired collateral vessel development in diabetes: potential cellular mechanisms and therapeutic implications. Cardiovasc Res 2001;49:554-560. (Pubitemid 32146418)
61. Rivard A, Silver M, Chen D, Kearney M, Magner M, Annex B et al. Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF. Am J Pathol 1999;154:355-363. (Pubitemid 29094086)
62. Emanueli C, Graiani G, Salis MB, Gadau S, Desortes E, Madeddu P. Prophylactic gene therapy with human tissue kallikrein ameliorates limb ischemia recovery in type 1 diabetic mice. Diabetes 2004;53:1096-1103. (Pubitemid 38436624)
63. Khan ZA, Chakrabarti S. Growth factors in proliferative diabetic retinopathy. Exp Diabesity Res 2003;4:287-301. (Pubitemid 38035568)
64. Wang XH, Qian RZ, Zhang W, Chen SF, Jin HM, Hu RM. MicroRNA-320 expression in myocardial microvascular endothelial cells and its relationship with insulin-like growth factor-1 in type 2 diabetic rats. Clin Exp Pharmacol Physiol 2009;36:181-188.
65. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of mammalian microRNA targets. Cell 2003;115:787-798. (Pubitemid 38058492)
66. John B, Enright AJ, Aravin A, Tuschl T, Sander C, Marks DS. Human MicroRNA targets. PLoS Biol 2004;2:e363.
67. Rabinovsky ED, Draghia-Akli R. Insulin-like growth factor I plasmid therapy promotes in vivo angiogenesis. Mol Ther 2004;9:46-55. (Pubitemid 38208327)
68. Li Y, Song YH, Li F, Yang T, Lu YW, Geng YJ. MicroRNA-221 regulates high glucose-induced endothelial dysfunction. Biochem Biophys Res Commun 2009;381: 81-83.
69. Poliseno L, Tuccoli A, Mariani L, Evangelista M, Citti L, Woods K et al. MicroRNAs modulate the angiogenic properties of HUVECs. Blood 2006;108:3068-3071.
70. Togliatto G, Trombetta A, Dentelli P, Rosso A, Brizzi MF. MIR221/MIR222-driven post-transcriptional regulation of P27KIP1 and P57KIP2 is crucial for high-glucoseand AGE-mediated vascular cell damage. Diabetologia 2011;54:1930-1940.
71. Villeneuve LM, Kato M, Reddy MA,Wang M, Lanting L, Natarajan R. Enhanced levels of microRNA-125b in vascular smooth muscle cells of diabetic db/db mice lead to increased inflammatory gene expression by targeting the histone methyltransferase Suv39h1. Diabetes 2010;59:2904-2915.
72. Villeneuve LM, Reddy MA, Lanting LL, Wang M, Meng L, Natarajan R. Epigenetic histone H3 lysine 9 methylation in metabolic memory and inflammatory phenotype of vascular smooth muscle cells in diabetes. Proc Natl Acad Sci USA 2008;105: 9047-9052.
73. Gallagher IJ, Scheele C, Keller P, Nielsen AR, Remenyi J, Fischer CP et al. Integration of microRNA changes in vivo identifies novel molecular features of muscle insulin resistance in type 2 diabetes. Genome Med 2010;2:9.
74. Caporali A, Meloni M, Vollenkle C, Bonci D, Sala-Newby GB, Addis R et al. Deregulation of microRNA-503 contributes to diabetes mellitus-induced impairment of endothelial function and reparative angiogenesis after limb ischemia. Circulation 2011;123:282-291.
75. Vickers KC, Remaley AT. MicroRNAs in atherosclerosis and lipoprotein metabolism. Curr Opin Endocrinol Diabetes Obes 2010;17:150-155.
76. Najafi-Shoushtari SH. MicroRNAs in Cardiometabolic Disease. Curr Atheroscler Rep 2011;13:202-207.
77. Chen JF, Mandel EM, Thomson JM, Wu Q, Callis TE, Hammond SM et al. The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat Genet 2006;38:228-233. (Pubitemid 43177239)
78. Care A, Catalucci D, Felicetti F, Bonci D, Addario A, Gallo P et al. MicroRNA-133 controls cardiac hypertrophy. Nat Med 2007;13:613-618. (Pubitemid 46828487)
79. Tian R, Abel ED. Responses of GLUT4-deficient hearts to ischemia underscore the importance of glycolysis. Circulation 2001;103:2961-2966. (Pubitemid 32578135)
80. Horie T, Ono K, Nishi H, Iwanaga Y, Nagao K, Kinoshita M et al. MicroRNA-133 regulates the expression of GLUT4 by targeting KLF15 and is involved in metabolic control in cardiac myocytes. Biochem Biophys Res Commun 2009;389:315-320.
81. Feng B, Chen S, George B, Feng Q, Chakrabarti S. miR133a regulates cardiomyocyte hypertrophy in diabetes. Diabetes Metab Res Rev 2010;26:40-49.
82. Aoyama T, Matsui T, Novikov M, Park J, Hemmings B, Rosenzweig A. Serum and glucocorticoid-responsive kinase-1 regulates cardiomyocyte survival and hypertrophic response. Circulation 2005;111:1652-1659. (Pubitemid 40525165)
83. Rossing P, Breum L, Major-Pedersen A, Sato A, Winding H, Pietersen A et al. Prolonged QTc interval predicts mortality in patients with type 1 diabetes mellitus. Diabet Med 2001;18:199-205. (Pubitemid 32397857)
84. Zhang Y, Xiao J, Lin H, Luo X, Wang H, Bai Y et al. Ionic mechanisms underlying abnormal QT prolongation and the associated arrhythmias in diabetic rabbits: a role of rapid delayed rectifier K+ current. Cell Physiol Biochem 2007;19:225-238. (Pubitemid 46701498)
85. Xiao J, Luo X, Lin H, Zhang Y, Lu Y, Wang N et al. MicroRNA miR-133 represses HERG K+ channel expression contributing to QT prolongation in diabetic hearts. J Biol Chem 2007;282:12363-12367. (Pubitemid 47100573)
86. Yoon YS, Uchida S, Masuo O, Cejna M, Park JS, Gwon HC et al. Progressive attenuation of myocardial vascular endothelial growth factor expression is a seminal event in diabetic cardiomyopathy: restoration of microvascular homeostasis and recovery of cardiac function in diabetic cardiomyopathy after replenishment of local vascular endothelial growth factor. Circulation 2005;111:2073-2085. (Pubitemid 40577902)
87. Li Y, Higashi Y, Itabe H, Song YH, Du J, Delafontaine P. Insulin-like growth factor-1 receptor activation inhibits oxidized LDL-induced cytochrome C release and apoptosis via the phosphatidylinositol 3 kinase/Akt signaling pathway. Arterioscler Thromb Vasc Biol 2003;23:2178-2184. (Pubitemid 37532317)
88. Yu XY, Song YH, Geng YJ, Lin QX, Shan ZX, Lin SG et al. Glucose induces apoptosis of cardiomyocytes via microRNA-1 and IGF-1. Biochem Biophys Res Commun 2008; 376:548-552.
89. Shan YX, Liu TJ, Su HF, Samsamshariat A, Mestril R, Wang PH. Hsp10 and Hsp60 modulate Bcl-2 family and mitochondria apoptosis signaling induced by doxorubicin in cardiac muscle cells. J Mol Cell Cardiol 2003;35:1135-1143. (Pubitemid 37083257)
90. Muraski JA, Fischer KM, Wu W, Cottage CT, Quijada P, Mason M et al. Pim-1 kinase antagonizes aspects of myocardial hypertrophy and compensation to pathological pressure overload. Proc Natl Acad Sci USA 2008;105:13889-13894.
91. Katare R, Caporali A, Zentilin L, Avolio E, Sala-Newby G, Oikawa A et al. Intravenous gene therapy with PIM-1 via a cardiotropic viral vector halts the progression of diabetic cardiomyopathy through promotion of prosurvival signaling. Circ Res 2011; 108:1238-1251.
92. Lu H, Buchan RJ, Cook SA. MicroRNA-223 regulates Glut4 expression and cardiomyocyte glucose metabolism. Cardiovasc Res 2010;86:410-420.
93. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 1984;102:527-532. (Pubitemid 14127839)
94. Shibuya M. Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J Biochem Mol Biol 2006;39:469-478. (Pubitemid 44714526)
95. McArthur K, Feng B, Wu Y, Chen S, Chakrabarti S. MicroRNA-200b regulates vascular endothelial growth factor-mediated alterations in diabetic retinopathy. Diabetes 2011;60:1314-1323.
96. Kovacs B, Lumayag S, Cowan C, Xu S. microRNAs in Early Diabetic Retinopathy in Streptozotocin-induced Diabetic Rats. Invest Ophthalmol Vis Sci 2011;52:4402-4409.
97. Kowluru RA, Koppolu P, Chakrabarti S, Chen S. Diabetes-induced activation of nuclear transcriptional factor in the retina, and its inhibition by antioxidants. Free Radic Res 2003;37:1169-1180. (Pubitemid 37322195)
98. Taganov KD, Boldin MP, Chang KJ, Baltimore D. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA 2006;103:12481-12486. (Pubitemid 44267285)
99. Gatto G, Rossi A, Rossi D, Kroening S, Bonatti S, Mallardo M. Epstein-Barr virus latent membrane protein 1 trans-activates miR-155 transcription through the NF-kappaB pathway. Nucleic Acids Res 2008;36:6608-6619.
100. Sheedy FJ, Palsson-McDermott E, Hennessy EJ, Martin C, O'Leary JJ, Ruan Q et al. Negative regulation of TLR4 via targeting of the proinflammatory tumor suppressor PDCD4 by the microRNA miR-21. Nat Immunol 2010;11:141-147.
101. Gilad S, Meiri E, Yogev Y, Benjamin S, Lebanony D, Yerushalmi N et al. Serum micro-RNAs are promising novel biomarkers. PLoS ONE 2008;3:e3148.
102. Hunter MP, Ismail N, Zhang X, Aguda BD, Lee EJ, Yu L et al. Detection of microRNA expression in human peripheral blood microvesicles. PLoS ONE 2008;3:e3694.
103. Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, Gibson DF et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci USA 2011;108:5003-5008.
104. Vickers AC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol 2001;13:423-433.
105. Zampetaki A, Kiechl S, Drozdov I, Willeit P, Mayr U, Prokopi M et al. Plasma micro-RNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res 2010;107:810-817.
106. Fish JE, Santoro MM, Morton SU, Yu S, Yeh RF, Wythe JD et al. miR-126 regulates angiogenic signaling and vascular integrity. Dev Cell 2008;15:272-284.
107. Wang S, Aurora AB, Johnson BA, Qi X, McAnally J, Hill JA et al. The endothelialspecific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell 2008;15:261-271.
108. Zernecke A, Bidzhekov K, Noels H, Shagdarsuren E, Gan L, Denecke B et al. Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Sci Signal 2009;2:ra81.
109. Waltenberger J, Lange J, Kranz A. Vascular endothelial growth factor-A-induced chemotaxis of monocytes is attenuated in patients with diabetes mellitus: a potential predictor for the individual capacity to develop collaterals. Circulation 2000;102: 185-190. (Pubitemid 30451775)
110. Kong L, Zhu J, HanW, Jiang X, Xu M, Zhao Y et al. Significance of serum microRNAs in pre-diabetes and newly diagnosed type 2 diabetes: a clinical study. Acta Diabetol 2011;48:61-69.
111. Kolfschoten IG, Roggli E, Nesca V, Regazzi R. Role and therapeutic potential of microRNAs in diabetes. Diabetes Obes Metab 2009;11(Suppl. 4):118-129.
112. Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature 2005;438:685-689.
113. Lanford RE, Hildebrandt-Eriksen ES, Petri A, Persson R, Lindow M, Munk ME et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 2010;327:198-201.
114. Snove O Jr, Rossi JJ. Expressing short hairpin RNAs in vivo. Nat Methods 2006;3: 689-695. (Pubitemid 44275735)
115. Kota J, Chivukula RR, O'Donnell KA, Wentzel EA, Montgomery CL, Hwang HW et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009;137:1005-1017.
116. Alexander IE, Cunningham SC, Logan GJ, Christodoulou J. Potential of AAV vectors in the treatment of metabolic disease. Gene Ther 2008;15:831-839. (Pubitemid 351712616)
117. Ebert MS, Neilson JR, Sharp PA. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat Methods 2007;4:721-726. (Pubitemid 47338166)
118. Valastyan S, Reinhardt F, Benaich N, Calogrias D, Szasz AM, Wang ZC et al. A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell 2009;137: 1032-1046.
119. Herrera BM, Lockstone HE, Taylor JM, Ria M, Barrett A, Collins S et al. Global microRNA expression profiles in insulin target tissues in a spontaneous rat model of type 2 diabetes. Diabetologia 2010;53:1099-1109.
120. Herrera BM, Lockstone HE, Taylor JM, Wills QF, Kaisaki PJ, Barrett A et al. Micro-RNA-125a is over-expressed in insulin target tissues in a spontaneous rat model of Type 2 Diabetes. BMC Med Genomics 2009;2:54.
121. Kloting N, Berthold S, Kovacs P, Schon MR, Fasshauer M, Ruschke K et al. MicroRNA expression in human omental and subcutaneous adipose tissue. PLoS One 2009;4: e4699.